NCT07362056

Implementing Suicide Prevention Into Primary Care in Nepal

Recruiting now NA Last updated 23 January 2026

What this trial tests

NA trial testing Suicide Prevention Package (PSuPP) in Suicide in 147 participants. Currently enrolling.

Timeline

15 November 2025

Primary endpoint
15 July 2027

15 August 2027

Quick facts

Lead sponsor	Yale University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	health services research
Enrollment	147
Start date	15 November 2025
Primary completion	15 July 2027
Estimated completion	15 August 2027
Sites	1 location across Nepal

Drugs / interventions tested

• Suicide Prevention Package (PSuPP)

Conditions studied

• Suicide — all drugs for Suicide →
• Primary Care — all drugs for Primary Care →

Sponsor

Yale University

Who can join

18 and older, any sex, with Suicide or Primary Care. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Suicide remains a major contributor to global mortality, with particularly high and persistent rates in low-resourced settings such as South Asia. In Nepal, ongoing integration of mental health services into primary care provides a critical opportunity to strengthen suicide risk assessment and management. Despite the scale-up of mhGAP training for primary care providers (PCPs), gaps remain in the systematic detection, referral, and follow-up of individuals at risk for suicide. There is an urgent need to enhance mhGAP implementation with strategies that address provider workload, stigma, and inequities within the health workforce.

Using experience-based co-design principles and RE-AIM this study will assess the feasibility and acceptability of integrating an implementation strategy package to optimize mhGAP suicide prevention delivery in Nepal's decentralized primary healthcare system. This clinical trial leverages deep collaboration with a community advisory board of individuals with lived experience of suicide throughout the trials' design, delivery and analysis.

This R34 will generate critical preliminary evidence on the feasibility, acceptability, and implementation of an integrated suicide prevention package within government primary care facilities in Nepal. The findings will inform the design and parameters of a future fully powered effectiveness trial, while aligning with Nepal's national suicide prevention strategy and advancing WHO and NIMH global mental health priorities.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.